SCHEMBL4698202

SCHEMBL4698202

Cc1ccc(NC(=O)c2ccc(F)c(C(F)(F)F)c2)cc1Nc1ncnc2c1cnn2C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 6/20 0.63
BRAF P15056 13/20 0.57
PIP4K2A P48426 2/20 0.54
ESYT2 A0FGR8 1/20 0.51
PLEKHG3 A1L390 1/20 0.51
NBAS A2RRP1 1/20 0.51
CNOT1 A5YKK6 1/20 0.51
TBKBP1 A7MCY6 1/20 0.51
MYO1G B0I1T2 1/20 0.51
AGPS O00116 1/20 0.51
MYO1F O00160 1/20 0.51
SNAP23 O00161 1/20 0.51
AP3B1 O00203 1/20 0.51
PSMD12 O00232 1/20 0.51
BMPR1B O00238 1/20 0.51
PGRMC1 O00264 1/20 0.51
CLIC1 O00299 1/20 0.51
CDC7 O00311 1/20 0.51
PDHX O00330 1/20 0.51
IPO5 O00410 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4697140 0.90 BRAF (0.66) MAPK14BRAF
SCHEMBL4699995 0.86 BRAF (0.68) MAPK14BRAF
SCHEMBL4696327 0.86 MAPK14 (0.61) MAPK14BRAFPIP4K2AESYT2PLEKHG3
SCHEMBL4698765 0.86 BRAF (0.61) MAPK14BRAFPIP4K2AESYT2PLEKHG3
SCHEMBL4697089 0.85 MAPK14 (0.58) MAPK14BRAFLMNALCKLYN
SCHEMBL4699786 0.85 BRAF (0.63) BRAFABL1EGFRLYNBCR
SCHEMBL4701699 0.84 BRAF (0.70) MAPK14BRAFPIP4K2AESYT2PLEKHG3
SCHEMBL12000876 0.78 MAPK14 (1.00) MAPK14MAPK11
SCHEMBL4698194 0.78 BRAF (0.61) MAPK14BRAFPIP4K2ALCKLYN
SCHEMBL4917090 0.78 BRAF (0.64) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963327-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS Novartis AG (CH) 2008-09-03 EP claimed
WO-2007062805-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-07 WO claimed
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors EPHB3, EPHB2, EPHB1 MAPK14 252/4885BRAF 42/4885PIP4K2A 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.